Pinion Investment Advisors LLC Has $694,000 Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Pinion Investment Advisors LLC lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.2% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,712 shares of the medical research company’s stock after selling 39 shares during the quarter. Pinion Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $694,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Financial Security Advisor Inc. bought a new position in Thermo Fisher Scientific in the second quarter valued at about $378,000. Callan Family Office LLC raised its position in Thermo Fisher Scientific by 34.9% in the second quarter. Callan Family Office LLC now owns 16,033 shares of the medical research company’s stock valued at $6,501,000 after purchasing an additional 4,146 shares during the last quarter. Court Place Advisors LLC raised its position in Thermo Fisher Scientific by 6.6% in the second quarter. Court Place Advisors LLC now owns 4,941 shares of the medical research company’s stock valued at $2,003,000 after purchasing an additional 305 shares during the last quarter. TFR Capital LLC. raised its position in Thermo Fisher Scientific by 20.5% in the second quarter. TFR Capital LLC. now owns 1,151 shares of the medical research company’s stock valued at $467,000 after purchasing an additional 196 shares during the last quarter. Finally, Boomfish Wealth Group LLC raised its position in Thermo Fisher Scientific by 30.5% in the second quarter. Boomfish Wealth Group LLC now owns 6,026 shares of the medical research company’s stock valued at $2,443,000 after purchasing an additional 1,407 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

TMO stock opened at $534.92 on Friday. The stock has a 50-day moving average price of $487.44 and a 200-day moving average price of $448.31. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The firm has a market cap of $201.99 billion, a PE ratio of 30.94, a price-to-earnings-growth ratio of 2.91 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same period last year, the company posted $5.37 EPS. The business’s quarterly revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Wall Street Analyst Weigh In

TMO has been the subject of several research reports. Evercore ISI increased their target price on Thermo Fisher Scientific from $525.00 to $590.00 and gave the company an “outperform” rating in a research report on Tuesday. Barclays lifted their target price on Thermo Fisher Scientific from $550.00 to $585.00 and gave the stock an “overweight” rating in a report on Thursday, October 2nd. Hsbc Global Res downgraded Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 24th. William Blair initiated coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They set an “outperform” rating on the stock. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Thermo Fisher Scientific in a report on Saturday, September 27th. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $593.43.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 30,066 shares of company stock worth $14,182,963. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.